Nebenwirkungen · Kineret
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 9
HOS-108752 · Präparat HOS-093075
There are no indications either from these studies or from post-marketing adverse reaction reports that the overall safety profile in patients with CAPS, FMF or Still’s disease is different from that in patients with RA, with the exception of the postmarketing observation of a higher frequency of reported hepatic events in patients with Still’s disease. The adverse reactions table below therefore applies to Kineret treatment of RA, CAPS, FMF and Still’s disease. During long term treatment of RA, CAPS, and Still’s disease the safety profile remains unchanged over time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-15T12:46:00Z · SHA-256 53a0a98f576dc350e42d4cc85e11cf9eeb4b97cf7707add713e0c1a596152e85 · Passage 83f6bf085a4544ffb7c5e0ed281ecf5fb1be0aa4c6c7b3c835fdb3bcbe947ade · Zeichen 2498–3072 im Abschnitt